An APOE4 gene test tells you which versions of a single gene you inherited. It does not tell you whether you will develop Alzheimer's disease. In the guides we publish at Longevity Benchmark, this is the result readers are most likely to receive without having chosen to look for it, because consumer genetic panels report it alongside ancestry and traits.
Apolipoprotein E (APOE) has three versions: APOE-ε2, APOE-ε3 and APOE-ε4, according to Cleveland Clinic. You carry two copies in total, one inherited from each parent, so your result is a pair, not a yes or no.
The Verdict
What the APOE Gene Does
APOE codes a protein that moves fats and cholesterol around the bloodstream and the brain. The three versions differ slightly in how well that protein does the job, which is why the same gene turns up in conversations about both dementia risk and lipid handling.
The three versions are not equal in effect. Cleveland Clinic describes APOE-ε2 as a version that "may protect you from Alzheimer's disease". APOE-ε3 is the version the other two are compared against. APOE-ε4 is the one that raises risk, and our news coverage of the UK Biobank dementia analysis describes it as the most common genetic risk factor for Alzheimer's disease. Having a risk-factor gene is a different situation from having a deterministic one, where inheriting the variant means the disease follows.
What One Copy and Two Copies Mean
Risk rises with the number of APOE4 copies you carry, and how far it rises is where published sources stop agreeing. The frequencies below come from Cleveland Clinic and describe how common each group is.
| Genotype | How common | What it means for risk |
|---|---|---|
| No copy of APOE4 | Most adults | The baseline risk for the population |
| One copy of APOE4 | An estimated 15% to 25% of people | Risk is raised above baseline |
| Two copies of APOE4 | An estimated 2% to 5% of people | Risk is raised further |
No lifetime-risk percentage appears in that table, and the omission is deliberate. Estimates published for single carriers and for people with two copies vary substantially depending on the population studied, the age followed to, and whether the outcome counted is Alzheimer's dementia or any cognitive impairment. Quoting one figure would make a contested number look settled. If a clinic or a report hands you a percentage, the useful question is which study it came from and who was in it.
The direction is not contested. Carrying APOE4 raises risk, and it does not make the disease inevitable. Cleveland Clinic states it plainly: "Just because you have at least one copy of this gene doesn't mean you'll develop Alzheimer's disease."
How the Test Is Done
The sample is easy to give. Cleveland Clinic describes a provider collecting DNA "either by blood test or by swabbing the inside of your cheek", and both routes read the same two positions in the gene. There is no fasting, no imaging, and no preparation.
The route matters more than the method. A clinically ordered test usually comes with someone whose job is to explain the result and to prepare you for it beforehand. A consumer genetic service can surface the same finding inside a dashboard, unprompted, months after you bought the kit for something else. Plan around that difference in framing, because the information itself is identical either way.
What the Result Cannot Tell You
An APOE4 result is not a diagnosis and cannot be read as one. Cleveland Clinic is explicit that the test "is not a diagnostic test" and that it "assesses your risk and doesn't confirm or deny a disease's presence in your body". It says nothing about whether disease is present now.
The same caution we applied to the UK Biobank subgroup finding holds here. A carrier who treats a risk figure as a personal forecast has over-read it. Knowing APOE status changes what a clinician weighs, and it does not by itself qualify anyone for a treatment.
What a Carrier Can Act On
A result does not by itself change what a clinician can prescribe, which surprises people who expected the test to settle something. The result changes your priorities. Your genotype is fixed for life, and the measurements sitting alongside it are not.
Because APOE codes a lipid-handling protein, the lipid side is the one most directly connected, and ApoB is the measurement that counts the particles carrying cholesterol into the artery wall. A carrier who has never measured ApoB has a more useful number available to them than the one they just received. Our guide to lowering biological age covers the rest of that list.
Who Should Skip the Test
Anyone who cannot say what they would do with a positive result should skip it, at least for now. The information is permanent, it cannot be returned, and it arrives without an action attached in most cases. That combination is the reason genetic counselling exists for this specific test.
Anyone still arranging life, disability or long-term care insurance should also wait. Those are exactly the three lines GINA does not cover, and the order in which you test and apply is a decision you only get to make once. Some states add their own protections, so the position depends on where you live.
We would change this answer on one condition. If a treatment arrived that a carrier became eligible for on the basis of APOE status alone, the case for testing would stop resting on motivation and start resting on access. Book a conversation with a genetic counsellor before you order an APOE4 gene test, and let that conversation decide it rather than the checkout page.
Frequently Asked Questions
What is an APOE4 gene test?
An APOE4 gene test reads which versions of the apolipoprotein E (APOE) gene you inherited. There are three: APOE-ε2, APOE-ε3 and APOE-ε4. You carry two copies in total, one from each parent, so a result names a pair such as ε3/ε4. The test is done on a blood sample or a swab of the inside of your cheek. It is a risk assessment rather than a diagnosis, and Cleveland Clinic states plainly that it "assesses your risk and doesn't confirm or deny a disease's presence in your body".
How do I know if I have the APOE4 gene?
A clinician can order the test, and several consumer genetic services report APOE status as part of a wider panel. Both routes read the same two positions in the gene. The two routes differ in what comes with the result. A clinical order usually arrives alongside someone whose job is to interpret it, while a consumer report can deliver the finding on a dashboard with no conversation attached. If you have already tested through a consumer service and never opened the APOE section, that decision is worth making deliberately rather than by accident.
What does one copy of APOE4 mean?
One copy raises your risk of Alzheimer's disease above the population baseline without making the disease likely. An estimated 15% to 25% of people carry one copy, which makes it common rather than rare. Published lifetime-risk estimates for single carriers differ substantially between sources, so treat any single percentage you are quoted with caution and ask where it came from. Cleveland Clinic's framing is the one to hold onto: "Just because you have at least one copy of this gene doesn't mean you'll develop Alzheimer's disease."
What does having two copies of APOE4 mean?
Two copies carry a higher risk than one. An estimated 2% to 5% of people are in this group. As with single carriers, published lifetime-risk figures vary widely between sources and none of them is a personal forecast. Practically, the result changes the weight a clinician gives it when discussing cognitive symptoms, follow-up, and the cardiovascular risk factors that are known to be modifiable. A genetic counsellor is the right person to work through a double-copy result with.
Is the APOE4 test covered by insurance?
Coverage varies, and it usually depends on whether a physician ordered the test to answer a specific clinical question rather than out of curiosity. Consumer genetic tests that report APOE status are paid for directly. A separate point matters more than the price. The Genetic Information Nondiscrimination Act (GINA) stops health insurers and employers from using genetic information against you, but the National Human Genome Research Institute notes that it "does not cover long-term care insurance, life insurance, or disability insurance". Some states add protections in those lines and many do not.
What should I do if I have the APOE4 gene?
Take the result to a clinician who can put it in context, and treat it as one input rather than an instruction. The test assesses risk and does not confirm or deny disease, so a result does not by itself change what a clinician can prescribe. It changes the weight given to the measurements already worth managing, starting with your lipids. Our guide to lowering biological age covers those levers, none of which requires a genetic result to justify.
Does APOE4 affect cholesterol?
The APOE gene codes a protein involved in moving lipids around the bloodstream, so which versions you carry does influence lipid handling. That is a different statement from a diagnosis of high cholesterol, and an APOE result never replaces measuring your lipids directly. If cholesterol is your concern, the more useful measurement is apolipoprotein B (ApoB), which counts the particles that actually carry cholesterol into the artery wall. Ask for that number before you order a gene test.
Can APOE4 be changed or removed?
No. Your APOE genotype is fixed at conception and stays the same for life, which is part of why the decision to look is worth making carefully. Nothing about the result is reversible, and it applies to your biological relatives as well as to you. Everything the risk sits alongside can still change. That is the practical reason the modifiable risk factors matter more to a carrier than to anyone else.
Related
- Genetic and methylation testing — what the other genomic tests in this category measure
- How to lower biological age — the modifiable levers behind the risk
- ApoB — the lipid measurement more actionable than a gene result
- Lipoprotein(a) — the other inherited risk marker, measured once in a lifetime
- DNA biomarkers — how a background risk allele like APOE4 differs from an actionable genetic result
- HRT and dementia risk in UK Biobank — the APOE subgroup finding and why it needs a caveat
- Coronary calcium score — the cardiovascular risk test that shares those modifiable factors